Rudick, RA and Stuart, WH and Calabresi, PA and Confavreux, C and Galetta, SL and Radue, EW and Lublin, FD and Weinstock-Guttman, B and Wynn, DR and Lynn, F and Panzara, MA and Sandrock, AW and Fazekas, F and Enzinger, C and Seifert, T and Storch, M and Strasser-Fuchs, S and Berger, T and Dilitz, E and Egg, R and Deisenhammer, F and Decoo, D and Lampaert, J and Bartholome, E and Bier, J and Stenager, E and Rasmussen, M and Binzer, M and Shorsh, K and Christensen, M and Ravnborg, M and Sorensen, PS and Blinkenberg, M and Petersen, B and Hansen, HJ and Bech, E and Petersen, T and Kirkegaard, M and Eralinna, J and Ruutiainen, J and Soilu-Hanninen, M and Sako, E and Laaksonen, M and Reunanen, M and Remes, A and Keskinarkaus, I and Moreau, T and Noblet, M and Rouaud, O and Couvreur, G and Edan, G and LePage, E and Drapier, S and De Burghgraeve, V and Yaouanq, J and Merienne, M and Cahagne, V and Gout, O and Deschamps, R and Le Canuet, P and Moulignier, A and Vermersch, P and De Seze, J and Stojkovic, T and Griffie, G and Engles, A and Ferriby, D and Debouverie, M and Pittion-Vouyouvitch, S and Lacour, JC and Pelletier, J and Feuillet, L and Suchet, L and Dalecky, A and Tammam, D and Lubetzki, C and Youssov, K and Mrejen, S and Charles, P and Yaici, S and Clavelou, P and Aufauvre, D and Renouil-Guy, N and Cesaro, P and Degos, F and Benisty, S and Rumbach, L and Decavel, P and Confavreux, C and Blanc, S and Aubertin, P and Riche, G and Brochet, B and Ouallet, JC and Anne, O and Menck, S and Grupe, A and Guttman, E and Lensch, E and Fucik, E and Heitmann, S and Hartung, HP and Schroter, M and Kurz, FMW and Heidenreich, F and Trebst, C and Pul, R and Hohlfeld, R and Krumbholz, M and Pellkofer, H and Haas, J and Segert, A and Anagnostou, P and Meyer, R and Kabus, C and Poehlau, D and Schneider, K and Hoffmann, V and Zettl, U and Steinhagen, V and Adler, S and Steinbrecher, A and Rothenfusser-Korber, E and Zellner, R and Baum, K and Gunther, A and Blasing, H and Stoll, G and Gold, R and Bayas, A and Kleinschnitz, C and Limmroth, V and Katsarava, Z and Kastrup, O and Haller, P and Stoeve, S and Hobel, D and Oschmann, P and Voigt, K and Burger, CV and Abramsky, O and Karusiss, D and Achiron, A and Kishner, I and Stern, Y and Sarove-Pinhas, I and Dolev, M and Magalashvili, D and Pozzili, C and Lenzi, D and Scontrini, A and Millefiorini, E and Buttinelli, C and Gallo, P and Ranzato, F and Tiberio, M and Perini, P and Laroni, A and Marrosu, M and Marchi, ECP and Spinicci, G and Massole, S and Mascia, M and Floris, G and Trojano, M and Bellacosa, A and Paolicelli, D and Zimatore, GB and Simone, IL and Giorelli, M and Di Monte, E and Mancardi, G and Pizzorno, M and Murialdo, A and Narciso, E and Capello, A and Comi, G and Martinelli, V and Rodegher, M and Esposito, F and Colombo, B and Rossi, P and Polman, CH and Jasperse, MMS and Zwemmer, JNP and Nielsen, J and Kragt, JJ and Jongen, PJH and De Smet, E and Tacken, H and Frequin, STFM and Siegers, HP and Mauser, HW and Fernandez-Fernandez, O and Leon, A and Romero, F and Alonso, A and Tamayo, J and Montalban, X and Nos, C and Pelayo, R and Tellez, N and Rio, J and Tintore, M and Arbizu, T and Romero, L and Moral, E and Martinez, S and Kappos, L and Achtnichts, L and Wilmes, S and Karabudak, R and Kurne, A and Erdem, S and Siva, A and Saip, S and Altintas, A and Atamer, A and Eraksoy, M and Bilgili, F and Topcular, B and Giovannoni, G and Lim, ET and Lava, N and Murnane, M and Dentinger, M and Zimmerman, E and Reiss, M and Gupta, V and Scott, T and Brillman, J and Kunschner, L and Wright, D and Perel, A and Babu, A (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. NEW ENGLAND JOURNAL OF MEDICINE, 354 (9). pp. 911-923. ISSN 0028-4793, 1533-4406
Full text not available from this repository. (Request a copy)Abstract
Background: Interferon beta is used to modify the course of relapsing multiple sclerosis. Despite interferon beta therapy, many patients have relapses. Natalizumab, an (alpha)(sub 4) integrin antagonist, appeared to be safe and effective alone and when added to interferon beta-1a in preliminary studies. Methods: We randomly assigned 1171 patients who, despite interferon beta-1a therapy, had had at least one relapse during the 12-month period before randomization to receive continued interferon beta-1a in combination with 300 mg of natalizumab (589 patients) or placebo (582 patients) intravenously every 4 weeks for up to 116 weeks. The primary end points were the rate of clinical relapse at 1 year and the cumulative probability of disability progression sustained for 12 weeks, as measured by the Expanded Disability Status Scale, at 2 years. Results: Combination therapy resulted in a 24 percent reduction in the relative risk of sustained disability progression (hazard ratio, 0.76; 95 percent confidence interval, 0.61 to 0.96; P=0.02). Kaplan-Meier estimates of the cumulative probability of progression at two years were 23 percent with combination therapy and 29 percent with interferon beta-1a alone. Combination therapy was associated with a lower annualized rate of relapse over a two-year period than was interferon beta-1a alone (0.34 vs. 0.75, P<0.001) and with fewer new or enlarging lesions on T(sub 2)-weighted magnetic resonance imaging (0.9 vs. 5.4, P<0.001). Adverse events associated with combination therapy were anxiety, pharyngitis, sinus congestion, and peripheral edema. Two cases of progressive multifocal leukoencephalopathy, one of which was fatal, were diagnosed in natalizumab-treated patients. Conclusions: Natalizumab added to interferon beta-1a was significantly more effective than interferon beta-1a alone in patients with relapsing multiple sclerosis. Additional research is needed to elucidate the benefits and risks of this combination treatment.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; RHEUMATOID-ARTHRITIS; T-CELLS; DISABILITY; THERAPY; METHOTREXATE; MULTICENTER; COMBINATION; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Neurologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 18 Feb 2021 07:57 |
| Last Modified: | 18 Feb 2021 07:57 |
| URI: | https://pred.uni-regensburg.de/id/eprint/34796 |
Actions (login required)
 |
View Item |
